Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III DAS181 vs placebo in parainfluenza lower respiratory tract infection in immunocompromised subjects
2018-004318-16Phase 3Terminated
- Sponsor
- Ansun Biopharma
- Start
- Nov 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in parainfluenza virus infection and airway morbidity comparing DAS181 (Farbefusp) with Placebo (2 arms). Primary endpoint: RTRA responders by Day 28. Started Nov 2019; status: terminated.
02
Drugs
DAS181
03
Conditions
parainfluenza virus infectionairway morbidity
Beyond the preview
Go deeper on 2018-004318-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004318-16.